Last reviewed · How we verify
Crofelemer Powder for Oral Solution
Crofelemer Powder for Oral Solution is a SGLT2 inhibitor Small molecule drug developed by Napo Therapeutics, S.p.A.. It is currently in Phase 2 development for Diarrhea-predominant irritable bowel syndrome (IBS-D).
Crofelemer is a plant-derived inhibitor of the sodium glucose cotransporter 2 (SGLT2)
Crofelemer is a plant-derived inhibitor of the sodium glucose cotransporter 2 (SGLT2) Used for Diarrhea-predominant irritable bowel syndrome (IBS-D).
At a glance
| Generic name | Crofelemer Powder for Oral Solution |
|---|---|
| Sponsor | Napo Therapeutics, S.p.A. |
| Drug class | SGLT2 inhibitor |
| Target | SGLT2 |
| Modality | Small molecule |
| Therapeutic area | Gastroenterology |
| Phase | Phase 2 |
Mechanism of action
Crofelemer works by inhibiting the SGLT2 protein in the kidneys, reducing glucose reabsorption and increasing glucose excretion in the urine.
Approved indications
- Diarrhea-predominant irritable bowel syndrome (IBS-D)
Common side effects
- Diarrhea
- Nausea
- Abdominal pain
Key clinical trials
- Open-Label Pilot Study With Crofelemer in Patients With Short Bowel Syndrome (EARLY_PHASE1)
- Ascending Doses of Crofelemer Powder for Oral Solution in Pediatric Microvillus Inclusion Disease (MVID) (PHASE2)
- Safety and Efficacy of Crofelemer in Adult Patients With Short Bowel Syndrome and Intestinal Failure (SBS-IF) Without Colon-in-continuity (CIC) (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Crofelemer Powder for Oral Solution CI brief — competitive landscape report
- Crofelemer Powder for Oral Solution updates RSS · CI watch RSS
- Napo Therapeutics, S.p.A. portfolio CI
Frequently asked questions about Crofelemer Powder for Oral Solution
What is Crofelemer Powder for Oral Solution?
How does Crofelemer Powder for Oral Solution work?
What is Crofelemer Powder for Oral Solution used for?
Who makes Crofelemer Powder for Oral Solution?
What drug class is Crofelemer Powder for Oral Solution in?
What development phase is Crofelemer Powder for Oral Solution in?
What are the side effects of Crofelemer Powder for Oral Solution?
What does Crofelemer Powder for Oral Solution target?
Related
- Drug class: All SGLT2 inhibitor drugs
- Target: All drugs targeting SGLT2
- Manufacturer: Napo Therapeutics, S.p.A. — full pipeline
- Therapeutic area: All drugs in Gastroenterology
- Indication: Drugs for Diarrhea-predominant irritable bowel syndrome (IBS-D)
- Compare: Crofelemer Powder for Oral Solution vs similar drugs
- Pricing: Crofelemer Powder for Oral Solution cost, discount & access